Yumanity Therapeutics Inc expected to post a loss of $1.13 a share - Earnings Preview

Kineta

12/11/2021 23:35

* Yumanity Therapeutics Inc  YMTX.OQ   YMTX.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 15 (estimated). 
* The Boston, Massachusetts-based company is expected to report
revenue of $1.933 million, according to the mean estimate from 3
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Yumanity Therapeutics
Inc is for a loss of $1.13 per share. For the same quarter last
year, the company reported a loss of $2.20 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Yumanity
Therapeutics Inc is $36​, about 85.4% above​ its last closing
price of $5.25. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2021  -0.83       -0.84      -1.03     Missed  -22.6
 Mar. 31 2021  -0.84       -0.83      -0.85     Missed  -2.4
 Dec. 31 2020              -2.80      3.96      Beat    241.4​
 Sep. 30 2020  -3.48       -3.60      -2.20     Beat    38.9
 ​​Jun.        -4.27       -4.25      -3.40     Beat    20
 30 2020                                                
 Mar. 31 2020  -5.34       -5.10      -3.80     Beat    25.5​
 Dec. 31 2019  -5.09       -5.75      -4.60     Beat    20
 Sep. 30 2019  -8.12       -8.10      -5.00     Beat    38.3
 This summary was machine generated November 12 at 23:35 GMT. 
All figures in US dollars  unless otherwise stated